β受体阻滞剂在心房颤动中的应用——试图理解令人不安的结果。
Beta-blockers in atrial fibrillation-trying to make sense of unsettling results.
机构信息
Department of Medicine, Lillehei Heart Institute, University of Minnesota, 2231 6th Street SE, Minneapolis, MN 55455, USA.
Department of Medicine, Cardiovascular Research Institute of Vermont, University of Vermont, Burlington, VT, USA.
出版信息
Europace. 2023 Feb 16;25(2):260-262. doi: 10.1093/europace/euad010.
Atrial fibrillation is closely associated with heart failure and adversely affects outcomes. Beta-blockers are strongly recommended to avoid rapid ventricular conduction and tachycardia-induced cardiomyopathy. In this Viewpoint article, we discuss an emerging body of evidence that questions beta-blockers as a preferred rate-control therapy in patients with atrial fibrillation.
心房颤动与心力衰竭密切相关，并对预后产生不利影响。β受体阻滞剂强烈推荐用于避免快速心室传导和心动过速性心肌病。在这篇观点文章中，我们讨论了越来越多的证据，这些证据对β受体阻滞剂作为心房颤动患者首选的心率控制治疗提出了质疑。
Zotero 插件